{"id":"loteprednol-etabonate-tobramycin-opthalmic-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival erythema"},{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL1200865","moleculeType":"Small molecule","molecularWeight":"466.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Loteprednol etabonate is a corticosteroid that suppresses inflammatory mediators and immune responses in the eye. Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, providing coverage against gram-negative and gram-positive bacteria. The combination addresses both inflammatory and infectious components of ocular disease.","oneSentence":"Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:04.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection"},{"name":"Post-operative ocular inflammation and infection prophylaxis"}]},"trialDetails":[{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zylet"],"phase":"marketed","status":"active","brandName":"loteprednol etabonate/tobramycin opthalmic suspension","genericName":"loteprednol etabonate/tobramycin opthalmic suspension","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis. Used for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk of bacterial infection, Post-operative ocular inflammation and infection prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}